Supplement Scholar
Metabolic / GLP-1

Exenatide

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Exenatide. The first approved GLP-1 receptor agonist, originally found in Gila monster saliva; lowers blood sugar and modestly reduces weight.

How it works. Activates GLP-1 receptors: increases insulin release when glucose is high, lowers glucagon, slows stomach emptying and reduces appetite.

What the research supports. 2 graded claims. Strongest: Lowers HbA1c in type 2 diabetes (strong).

Hormonal impact. Effects on Insulin, Glucagon.

Side effects and interactions. 3 medication interactions listed. Serious: Pancreatitis.

Stacking. Avoid combining with Other GLP-1 drugs.

Common forms. Available as Twice-daily injection (Byetta), Weekly injection (Bydureon BCise).

Community. Experiences from people who have tried Exenatide. Anecdotes are not medical advice.

Exenatide. The first approved GLP-1 receptor agonist, originally found in Gila monster saliva; lowers blood sugar and modestly reduces weight.

39-residue chainC184H282N50O60S · 4187 g/mol

What it is

Synthetic exendin-4, approved for type 2 diabetes as a twice-daily (Byetta) or weekly (Bydureon) injection. Weight loss is smaller than with semaglutide or tirzepatide.

Also called

ByettaBydureonExendin-4

How it works

Activates GLP-1 receptors: increases insulin release when glucose is high, lowers glucagon, slows stomach emptying and reduces appetite.

Pathways

  • GLP-1 receptor agonism
  • Glucose-dependent insulin release
  • Slower gastric emptying

Effects

  • ↓Blood glucose decreases
  • ↓Appetite decreases
  • ↓Stomach emptying rate decreases

What the research supports

Lowers HbA1c in type 2 diabetesstrong
Modest weight loss (about 2–4 kg)moderate

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑Insulinincreases
↓Glucagondecreases

Side effects & interactions

Common side effects

  • Nausea
  • Vomiting
  • Injection-site nodules (weekly form)

Serious

  • Pancreatitis
  • Kidney injury from dehydration
  • Thyroid C-cell tumor warning (weekly form; avoid with MEN2 or medullary thyroid cancer history)

Medication interactions

Insulin / sulfonylureasmoderate

Higher risk of low blood sugar.

Warfarinmoderate

INR increases reported; monitor.

Oral drugs needing fast absorptionminor

Slowed stomach emptying delays absorption.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Avoid combining

  • Other GLP-1 drugsDuplicate therapy.

Common forms

  • Twice-daily injection (Byetta)
  • Weekly injection (Bydureon BCise)

Discussion

Loading discussion…